Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Oxytocin

FDA-approved product (solution, nasal), marketed as Oxytocin, Oxytocin 10 Usp Units In Dextrose 5%, Oxytocin 20 Usp Units In Dextrose 5% and 3 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Oxytocin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hemorrhage
  • Uterine Inertia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Oxytocin and analogues
FDA pharmacologic class
Oxytocic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA74.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli55.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae52.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Oxytocin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Oxytocin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Glutamatergic Amino Acids and Oxytocin Levels in the Plasma of Patients in First Psychotic Episode (FPE)- Before and After Neuroleptic Treatment

    NCT00789022 · start 2009-01

    Registered record
    Registry ID
    NCT00789022
    Conditions
    Schizophrenia; Schizophreniform; Schizoaffective Disorder; Brief Psychotic Episode
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2009-01
    Completion
    Not recorded
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizophreniform; Schizoaffective Disorder; Brief Psychotic Episode
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Effects of Oxytocin on Behavior and Physiology in a Psychotherapy Setting

    NCT01081249 · start 2008-12

    Registered record
    Registry ID
    NCT01081249
    Conditions
    Behavior; Anxiety
    Interventions
    Placebo then intranasal oxytocin; Intranasal oxytocin then placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-12
    Completion
    2012-07
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBehavior; Anxiety
    InterventionPlacebo then intranasal oxytocin; Intranasal oxytocin then placebo
    PhasePhase 4
    Registry statusCompleted

  • Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome

    NCT01254045 · start 2007-02

    Registered record
    Registry ID
    NCT01254045
    Conditions
    Fragile X Syndrome
    Interventions
    placebo; oxytocin 24IU; oxytocin 48IU
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-02
    Completion
    2010-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFragile X Syndrome
    Interventionplacebo; oxytocin 24IU; oxytocin 48IU
    PhasePhase 2
    Registry statusCompleted

  • Third Stage of Labor a Swedish Randomized Controlled Trial

    NCT01221051 · start 2006-11

    Registered record
    Registry ID
    NCT01221051
    Conditions
    Childbirth
    Interventions
    active management of the third stage of labor; expectant management of the third stage of labor
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-11
    Completion
    2008-04
    Enrolment
    1,800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChildbirth
    Interventionactive management of the third stage of labor; expectant management of the third stage of labor
    PhaseNot applicable
    Registry statusCompleted

  • Identifying the Role of Oxytocin and Vasopressin in the Functioning of Neurocognitive Systems Involved in Mood Disorders

    NCT00325065 · start 2006-05-05

    Registered record
    Registry ID
    NCT00325065
    Conditions
    Mood Disorders
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2006-05-05
    Completion
    2010-04-16
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMood Disorders
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted